Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors

• Published in: Molecular diagnosis & therapy 2023-11, Vol.27 (6), p.753-768
• Main Authors: Zhao, Jianhua, Reuther, Jacquelyn, Scozzaro, Kaylee, Hawley, Megan, Metzger, Emily, Emery, Matthew, Chen, Ingrid, Barbosa, Michelle, Johnson, Laura, O’Connor, Alijah, Washburn, Mike, Hartje, Luke, Reckase, Erik, Johnson, Verity, Zhang, Yuhua, Westheimer, Emily, O’Callaghan, William, Malani, Nirav, Chesh, Adrian, Moreau, Michael, Daber, Robert
• Format: Article
• Language: English
• Subjects: Accuracy; Alleles; Assaying; Biomarkers; Biomedical and Life Sciences; Biomedicine; Biopsy; Bone marrow; Cancer; Cancer Research; Cancer therapies; Customization; DNA sequencing; Gene frequency; Human Genetics; Laboratory Medicine; Lung cancer; Metastasis; Minimal residual disease; Molecular Medicine; Monitoring; Mutation; Next-generation sequencing; Original; Original Research Article; Panels; Patients; Peripheral blood; Pharmacotherapy; Plasma; Polymerase chain reaction; Reproducibility; Sensitivity; Solid tumors; Telemedicine; Tumors
• ISSN: 1177-1062; 1179-2000
• DOI: 10.1007/s40291-023-00670-1

Background Highly sensitive molecular assays have been developed to detect plasma-based circulating tumor DNA (ctDNA), and emerging evidence suggests their clinical utility for monitoring minimal residual disease and recurrent disease, providing prognostic information, and monitoring therapy responses in patients with solid tumors. The Invitae Personalized Cancer Monitoring ™ assay uses a patient-specific, tumor-informed variant signature identified through whole exome sequencing to detect ctDNA in peripheral blood of patients with solid tumors. Methods The assay’s tumor whole exome sequencing and ctDNA detection components were analytically validated using 250 unique human specimens and nine commercial reference samples that generated 1349 whole exome sequencing and cell-free DNA (cfDNA)-derived libraries. A comparison of tumor and germline whole exome sequencing was used to identify patient-specific tumor variant signatures and generate patient-specific panels, followed by targeted next-generation sequencing of plasma-derived cfDNA using the patient-specific panels with anchored multiplex polymerase chain reaction chemistry leveraging unique molecular identifiers. Results Whole exome sequencing resulted in overall sensitivity of 99.8% and specificity of > 99.9%. Patient-specific panels were successfully designed for all 63 samples (100%) with ≥ 20% tumor content and 24 (80%) of 30 samples with ≥ 10% tumor content. Limit of blank studies using 30 histologically normal, formalin-fixed paraffin-embedded specimens resulted in 100% expected panel design failure. The ctDNA detection component demonstrated specificity of > 99.9% and sensitivity of 96.3% for a combination of 10 ng of cfDNA input, 0.008% allele frequency, 50 variants on the patient-specific panels, and a baseline threshold. Limit of detection ranged from 0.008% allele frequency when utilizing 60 ng of cfDNA input with 18–50 variants in the patient-specific panels (> 99.9% sensitivity) with a baseline threshold, to 0.05% allele frequency when using 10 ng of cfDNA input with an 18-variant panel with a monitoring threshold (> 99.9% sensitivity). Conclusions The Invitae Personalized Cancer Monitoring assay, featuring a flexible patient-specific panel design with 18–50 variants, demonstrated high sensitivity and specificity for detecting ctDNA at variant allele frequencies as low as 0.008%. This assay may support patient prognostic stratification, provide real-time data on therapy responses, and enabl